Mr. Hugh MacNaught reports

VENTRIPOINT ENGAGES MORE CAPITAL LTD.

Ventripoint Diagnostics Ltd. has engaged More Capital Ltd., a Toronto, Ontario-based, private investment and strategic advisory firm, under a strategic growth and advisory agreement focused on commercial partnerships, market expansion and broader awareness of the company's technology, subject to acceptance by the TSX Venture Exchange.

The engagement is intended to create greater awareness of Ventripoint's commercialization program to drive adoption of its Food and Drug Administration-cleared VMS+ system. More Capital is being compensated at a rate of $13,000 per month for an initial term of three months, subject to renewal by mutual agreement.

About Ventripoint Diagnostics Ltd.

Ventripoint Diagnostics has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS (vertical market software) products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.